Clinical trial
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver…
NCT00247676 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00247676 |
|---|---|
| Title | An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer |
| Official title | An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Unresectable Hepatocellular Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Neoplasms, Unresectable Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Sunitinib (SU011248) |
| Enrollment | 37 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Nov 2, 2005 |
| Last update posted | Feb 18, 2010 |
| Countries | France, South Korea, Taiwan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: